New publications in health economics and genomics 22nd September 2020

Three publications from the past week:

  • A three-year follow-up study evaluating clinical utility of exome sequencing and diagnostic potential of reanalysis | link
  • Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology | link
  • Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 8th September 2020

Two publications from the last week:

  • Efficacy and economics of targeted panel versus whole exome sequencing in 878 patients with suspected primary immunodeficiency | link
  • Genomic Testing for Relapsed and Refractory Lymphoid Cancers: Understanding Patient Values | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 1st September 2020

One publication from the last week:

  • The value of genomic sequencing in complex pediatric neurological disorders: a discrete choice experiment | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 25th August 2020

Two publications from the last week:

  • Clinical and Economic Outcomes of Genome Sequencing Availability on Containing a Hospital Outbreak of Resistant Escherichia coli in Australia | link
  • Health-care practitioners’ preferences for the return of secondary findings from next-generation sequencing: a discrete choice experiment | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 18th August 2020

Two publications from the last week:

  • Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment | link
  • A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 11th August 2020

Two publications from the last two weeks:

  • Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer | link
  • PARC report: a health-systems focus on reimbursement and patient access to pharmacogenomics testing | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 21st July 2020

One publication this week:

  • Next generation use in Oncology, a better information on patients’ genetic profiles improved access to matched treatments and earlier NGS use show better outcomes | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 14th July 2020

Three publications this week:

  • PARC report: health outcomes and value of personalized medicine interventions: impact on patient care | link
  • The Daunting Economics of Therapeutic Genome Editing | link
  • Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 7th July 2020

No publications last week, but five (well, kind of) this week:

  • Costs of In-House Genomic Profiling and Implications for Economic Evaluation: A Case Example of Non-Small Cell Lung Cancer (NSCLC) | link
  • Multi-gene Assays: Effect on Chemotherapy Use, Toxicity and Cost in Estrogen Receptor-Positive Early Stage Breast Cancer | link
  • Ending the Diagnostic Odyssey—Is Whole-Genome Sequencing the Answer? | link
  • Economic Value of Exome Sequencing for Suspected Monogenic Disorders [letter] | link
  • Response to Ferket Et Al [response to letter] | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.

New publications in health economics and genomics 23rd June 2020

No publications last week, but a glut of new publications related to multi-gene panels this week, four in total:

  • Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention | link
  • Projected Cost-Effectiveness for 2 Gene-Drug Pairs Using a Multigene Panel for Patients Undergoing Percutaneous Coronary Intervention | link
  • Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer | link
  • Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis | link

I’m happy to share any other publications from this week that I’ve missed – just let me know.